Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Eligibility Criteria

• * Diagnosis B-cell NHL: Burkitt lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Follicular Lymphoma, Richter syndrome, and CD20+ Hodgkin Lymphoma.
• * Disease Status Primary Induction Failure, 1st, 2nd or 3rd relapse/progression having attained a CR, PR, or stable disease post reinduction therapy.
• * Performance Level Patients must have a performance status ≥ 50%. Use Karnofsky for patients \> 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.
• * Life Expectancy Patients must have a life expectancy of \> 6 weeks.
• * Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
• 1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).
• 2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.
• * Organ Function Requirements
• * Creatinine clearance or radioisotope GFR \> 60 mL/min/1.73 m2 or
• * A serum creatinine based on age/gender as follows:
• * 12 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4
• * 16 years 1.7 1.4
• * Adequate Liver Function Defined As:
• * Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for age, and
• * SGOT (AST) or SGPT (ALT) \< 3 x upper limit of normal (ULN) for age for presumed hepatic leukemia or lymphoma.
• * Adequate Cardiac Function Defined As:
• * Shortening fraction of \> 27% by echocardiogram, or
• * Ejection fraction of \> 50% by radionuclide angiogram.
• * Adequate Pulmonary Function Defined As:
• * Peripheral Blood Stem Cell Collection
• * All patients and/or their parents or legal guardians must sign a written informed consent.
• * Patient may not have had a prior stem cell transplant
• * Patients must not have active CNS lymphoma
• * Other concurrent investigational agents for treatment of B-cell lymphoma
• * Pregnancy and/or active Breast Feeding
• * Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.
• * Patient must not have an uncontrolled infection.
• * Patient must not have ≥ Grade 3 neuropathy.